Reiss KA et al. -Sorafenib is first-line therapy for advanced hepatocellular carcinoma; however, the starting dose has not been established. In the current study, sorafenib therapy at ra educed dose was shown to be associated with reduced pill use, reduced costs, and a decreased discontinuation rate. Importantly, reduced dosing was not associated with decreased overall survival.